| 达格列净治疗2型糖尿病的临床研究 |
| |
| 引用本文： | 孙伟,王飞,杨光束,于影. 达格列净治疗2型糖尿病的临床研究[J]. 中华全科医学, 2021, 19(8): 1303-1305. DOI: 10.16766/j.cnki.issn.1674-4152.002046 |
| |
| 作者姓名： | 孙伟 王飞 杨光束 于影 |
| |
| 作者单位： | 1.淮北市人民医院内分泌科, 安徽 淮北 235000 |
| |
| 基金项目： | 安徽省教育厅自然科学重点项目KJ2019A0306淮北市2018年科技攻关计划rj201810 |
| |
| 摘 要： | 目的 观察达格列净联合预混胰岛素治疗血糖控制较差的2型糖尿病患者的临床疗效、安全性及耐受性.方法 选择2019年1月-2020年3月期间于淮北市人民医院住院的60例注射门冬胰岛素30与二甲双胍口服联合治疗血糖控制不达标的2型糖尿病患者,根据临床治疗方法分为2组,每组30例,对照组使用门冬胰岛素30注射联合二甲双胍口服,...
|
| 关 键 词： | 2型糖尿病 达格列净 门冬胰岛素30 钠葡萄糖协同转运蛋白2抑制剂 |
| 收稿时间： | 2021-07-11 |
Clinical efficacy of dapagliflozin in the treatment of type 2 diabetes mellitus |
| |
| Affiliation: | Department of Endocrinology, Huaibei People's Hospital, Huaibei, Anhui 235000, China |
| |
| Abstract: | Objective To observe the clinical therapeutic effect, safety and tolerance of dapagliflozin combined with premix insulin in treatment for type 2 diabetes mellitus with poor glucose control. Methods Total 60 patients with type 2 diabetes mellitus with poor glycemic control treated with oral insulin aspartate 30 and metformin were treated in Huaibei People's Hospital from January 2019 to March 2020 were divided into 2 groups, 30 cases in each group according to the clinical treatment. The observation group received the treatment of dapagliflozin combined with insulin aspart 30 and metformin, and the control group was only treated with insulin aspart 30 and metformin. Two groups of the patients adjust insulin dose according to the level of plasma glucose. The patient's fasting plasma glucose (FPG), 2-hour postprandial blood glucose (2hPG), hemoglobin A1c (HbA1c), plasma glucose controlling time, insulin doses, presence of hypoglycemic events, weight change and adverse reaction were recorded. Results After 12 weeks of treatment, the fasting plasma glucose, 2-hour postprandial blood glucose and hemoglobin A1c in the two groups were lower than before treatment (P < 0.05). Fasting plasma glucose (6.60±0.52) mmol/L, plasma glucose controlling time (6.67±1.60) d, insulin dosage (40.17±7.01) U/d and body mass index (23.41±2.11) in the observation group were lower than the control group (P < 0.05). Two patients in the observation group had hypoglycemia, while eight patients in the control group had hypoglycemia. The incidence of hypoglycemia in the control group was higher than that in the observation group. There was statistical difference between the two groups (P < 0.05). Conclusion The clinical efficacy of dapagliflozin combined with premix insulin is significant in the treatment of type 2 diabetes. It has the advantages of weight loss, good safety and tolerance. |
| |
| Keywords: | |
|
| 点击此处可从《中华全科医学》浏览原始摘要信息 |
|
点击此处可从《中华全科医学》下载免费的PDF全文 |
|
